IBDEI1AP ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22025,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,22025,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,22026,0)
 ;;=E11.39^^87^973^18
 ;;^UTILITY(U,$J,358.3,22026,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22026,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Ophthalmic Complication NEC
 ;;^UTILITY(U,$J,358.3,22026,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,22026,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,22027,0)
 ;;=E11.43^^87^973^15
 ;;^UTILITY(U,$J,358.3,22027,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22027,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Autonomic Neuropathy
 ;;^UTILITY(U,$J,358.3,22027,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,22027,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,22028,0)
 ;;=E11.59^^87^973^13
 ;;^UTILITY(U,$J,358.3,22028,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22028,1,3,0)
 ;;=3^DM Type 2 w/ Circulatory Complications NEC
 ;;^UTILITY(U,$J,358.3,22028,1,4,0)
 ;;=4^E11.59
 ;;^UTILITY(U,$J,358.3,22028,2)
 ;;=^5002652
 ;;^UTILITY(U,$J,358.3,22029,0)
 ;;=E11.618^^87^973^14
 ;;^UTILITY(U,$J,358.3,22029,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22029,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Arthropathy NEC
 ;;^UTILITY(U,$J,358.3,22029,1,4,0)
 ;;=4^E11.618
 ;;^UTILITY(U,$J,358.3,22029,2)
 ;;=^5002654
 ;;^UTILITY(U,$J,358.3,22030,0)
 ;;=E11.621^^87^973^16
 ;;^UTILITY(U,$J,358.3,22030,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22030,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Foot Ulcer
 ;;^UTILITY(U,$J,358.3,22030,1,4,0)
 ;;=4^E11.621
 ;;^UTILITY(U,$J,358.3,22030,2)
 ;;=^5002656
 ;;^UTILITY(U,$J,358.3,22031,0)
 ;;=E11.622^^87^973^20
 ;;^UTILITY(U,$J,358.3,22031,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22031,1,3,0)
 ;;=3^DM Type 2 w/ Skin Ulcer NEC
 ;;^UTILITY(U,$J,358.3,22031,1,4,0)
 ;;=4^E11.622
 ;;^UTILITY(U,$J,358.3,22031,2)
 ;;=^5002657
 ;;^UTILITY(U,$J,358.3,22032,0)
 ;;=E11.65^^87^973^19
 ;;^UTILITY(U,$J,358.3,22032,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22032,1,3,0)
 ;;=3^DM Type 2 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,22032,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,22032,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,22033,0)
 ;;=E11.9^^87^973^21
 ;;^UTILITY(U,$J,358.3,22033,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22033,1,3,0)
 ;;=3^DM Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,22033,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,22033,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,22034,0)
 ;;=E13.9^^87^973^22
 ;;^UTILITY(U,$J,358.3,22034,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22034,1,3,0)
 ;;=3^Diabetes Mellitus (Secondary) w/o Complications NEC
 ;;^UTILITY(U,$J,358.3,22034,1,4,0)
 ;;=4^E13.9
 ;;^UTILITY(U,$J,358.3,22034,2)
 ;;=^5002704
 ;;^UTILITY(U,$J,358.3,22035,0)
 ;;=E16.2^^87^973^29
 ;;^UTILITY(U,$J,358.3,22035,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22035,1,3,0)
 ;;=3^Hypoglycemia,Unspec
 ;;^UTILITY(U,$J,358.3,22035,1,4,0)
 ;;=4^E16.2
 ;;^UTILITY(U,$J,358.3,22035,2)
 ;;=^5002708
 ;;^UTILITY(U,$J,358.3,22036,0)
 ;;=E20.0^^87^973^34
 ;;^UTILITY(U,$J,358.3,22036,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22036,1,3,0)
 ;;=3^Idiopathic Hypoparathyroidism
 ;;^UTILITY(U,$J,358.3,22036,1,4,0)
 ;;=4^E20.0
 ;;^UTILITY(U,$J,358.3,22036,2)
 ;;=^5002712
 ;;^UTILITY(U,$J,358.3,22037,0)
 ;;=E20.9^^87^973^30
 ;;^UTILITY(U,$J,358.3,22037,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22037,1,3,0)
 ;;=3^Hypoparathyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,22037,1,4,0)
 ;;=4^E20.9
 ;;^UTILITY(U,$J,358.3,22037,2)
 ;;=^5002714
 ;;^UTILITY(U,$J,358.3,22038,0)
 ;;=E23.0^^87^973^31
 ;;^UTILITY(U,$J,358.3,22038,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22038,1,3,0)
 ;;=3^Hypopituitarism
